van de Veerdonk Wessel, Hoeck Sarah, Peeters Marc, Van Hal Guido, Francart Julie, De Brabander Isabel
Faculty of Medicine and Health Sciences, Department of Social Epidemiology and Health Policy, University of Antwerp, Antwerp, Belgium.
Centre for Cancer Detection, Bruges/Antwerp, Belgium.
United European Gastroenterol J. 2020 Mar;8(2):185-194. doi: 10.1177/2050640619882157. Epub 2019 Oct 3.
Colorectal cancer (CRC) and its precursor lesions are detected at an early stage by CRC screening programmes, which reduce CRC-related mortality. An important quality indicator for CRC screening is the occurrence of interval CRC (IC) between screening rounds. Currently there is no guideline regarding acceptable levels of ICs in CRC screening programmes, and ICs reported in prior work vary considerably.
This study describes the occurrence of screen-detected (SD) CRC and non-screen-detected CRC within the population-based CRC screening programme of Flanders, stratified by multiple variables such as sex, age, tumour location and tumour stage between October 2013 and July 2017. In addition, faecal immunochemical test (FIT) IC proportions over the sum of SD-CRCs and FIT-ICs are calculated, together with FIT sensitivity and programme sensitivity to display the effectiveness of detecting CRC by the screening programme.
Of 1,212,354 FIT participants, 4094 were diagnosed with SD-CRC, whereas 772 participants were diagnosed with CRC between FIT-screening rounds. Significant associations were shown between people not being SD for CRC and women, older individuals, right-sided tumour location and more advanced tumour stage. Furthermore, a clear distinction was shown between the right-sided and the left-sided colorectum concerning all above-mentioned variables and distributions of tumour stages.
The Flemish FIT-interval CRC proportion of 15.9% was within the limits of previously published results. In addition, calculations show that the effectiveness of the screening programme is dependent on tumour location, suggesting that future research should report results stratified by location.
结直肠癌(CRC)筛查项目可在早期发现结直肠癌及其前驱病变,从而降低结直肠癌相关死亡率。结直肠癌筛查的一项重要质量指标是筛查轮次之间间隔期结直肠癌(IC)的发生率。目前尚无关于结直肠癌筛查项目中IC可接受水平的指南,先前研究报道的IC发生率差异很大。
本研究描述了2013年10月至2017年7月期间,在弗拉芒地区基于人群的结直肠癌筛查项目中,筛查发现的(SD)结直肠癌和非筛查发现的结直肠癌的发生情况,并按性别、年龄、肿瘤位置和肿瘤分期等多个变量进行分层。此外,计算粪便免疫化学检测(FIT)IC占SD-CRC和FIT-IC总和的比例,以及FIT敏感性和项目敏感性,以显示筛查项目检测结直肠癌的有效性。
在1,212,354名接受FIT检测的参与者中,4094人被诊断为SD-CRC,而772名参与者在FIT筛查轮次之间被诊断为结直肠癌。未被筛查出患有结直肠癌的人群与女性、老年人、右侧肿瘤位置和更晚期肿瘤分期之间存在显著关联。此外,在上述所有变量以及肿瘤分期分布方面,右侧和左侧结直肠之间存在明显差异。
弗拉芒地区FIT间隔期结直肠癌比例为15.9%,在先前公布的结果范围内。此外,计算结果表明筛查项目的有效性取决于肿瘤位置,这表明未来的研究应按位置分层报告结果。